title: Hypoxic intensity: a determinant for the contribution of ATP and adenosine to the genesis of carotid body chemosensory activity.
abstract: Excitatory effects of adenosine and ATP on carotid body (CB) chemoreception have been previously described. Our hypothesis is that both ATP and adenosine are the key neurotransmitters responsible for the hypoxic chemotransmission in the CB sensory synapse, their relative contribution depending on the intensity of hypoxic challenge. To test this hypothesis we measured carotid sinus nerve (CSN) activity in response to moderate and intense hypoxic stimuli (7 and 0% O(2)) in the absence and in the presence of adenosine and ATP receptor antagonists. Additionally, we quantified the release of adenosine and ATP in normoxia (21% O(2)) and in response to hypoxias of different intensities (10, 5, and 2% O(2)) to study the release pathways. We found that ZM241385, an A(2) antagonist, decreased the CSN discharges evoked by 0 and 7% O(2) by 30.8 and 72.5%, respectively. Suramin, a P(2)X antagonist, decreased the CSN discharges evoked by 0 and 7% O(2) by 64.3 and 17.1%, respectively. Simultaneous application of both antagonists strongly inhibited CSN discharges elicited by both hypoxic intensities. ATP release by CB increased in parallel to hypoxia intensity while adenosine release increased preferably in response to mild hypoxia. We have also found that the lower the O(2) levels are, the higher is the percentage of adenosine produced from extracellular catabolism of ATP. Our results demonstrate that ATP and adenosine are key neurotransmitters involved in hypoxic CB chemotransduction, with a more relevant contribution of adenosine during mild hypoxia, while vesicular ATP release constitutes the preferential origin of extracellular adenosine in high-intensity hypoxia.
authors.affiliation: CEDOC, Departamento de Farmacologia, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal. silvia.conde@fcm.unl.pt
authors.forename: S V
authors.initials: SV
authors.lastname: Conde
authors.forename: E C
authors.initials: EC
authors.lastname: Monteiro
authors.forename: R
authors.initials: R
authors.lastname: Rigual
authors.forename: A
authors.initials: A
authors.lastname: Obeso
authors.forename: C
authors.initials: C
authors.lastname: Gonzalez
mesh_terms: D000241:Adenosine / Q000378:metabolism*; D000255:Adenosine Triphosphate / Q000378:metabolism*; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002344:Carotid Body / Q000187:drug effects / Q000378:metabolism*; D002346:Carotid Sinus / Q000187:drug effects / Q000378:metabolism; D002628:Chemoreceptor Cells / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D000860:Hypoxia / Q000378:metabolism*; D008297:Male; D053858:Metabolic Networks and Pathways / Q000187:drug effects; D018377:Neurotransmitter Agents / Q000378:metabolism; D010100:Oxygen / Q000008:administration & dosage / Q000378:metabolism*; D058915:Purinergic P1 Receptor Antagonists / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D018048:Receptors, Purinergic P2 / Q000378:metabolism; D013569:Synapses / Q000187:drug effects / Q000378:metabolism
chemical_list: D018377:Neurotransmitter Agents; D058915:Purinergic P1 Receptor Antagonists; D018048:Receptors, Purinergic P2; D000255:Adenosine Triphosphate; D000241:Adenosine; D010100:Oxygen; D002118:Calcium